-
Jazz Pharma Getting New State-Of-The-Art Facility For Cannabis-Based Research And Production
Friday, March 25, 2022 - 9:00am | 420Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million. The new facility, expected to be...
-
Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma
Thursday, March 3, 2022 - 9:30am | 777The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC) against GW Pharmaceuticals on Feb. 25th. The lawsuit was initially filed in 2020, and since then, Britain’s GW Pharma was...
-
Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results
Tuesday, March 1, 2022 - 7:12pm | 709Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...
-
Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B
Wednesday, August 4, 2021 - 10:29am | 657Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the comparative period of 2020. Financial...
-
Does Big Business Provide A Better Look Into Cannabis Reform Than Capitol Hill? Operators Believe So.
Thursday, July 29, 2021 - 9:20am | 874Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regulatory activity than the federal government. At the very least, they say that the industry has made advancements so far without the efforts of Capitol Hill....
-
Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio
Thursday, May 6, 2021 - 10:16am | 387The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders. The Jazz-GW...
-
Earnings Roundup: Neptune, Item9, GW Pharmaceuticals
Tuesday, February 16, 2021 - 1:31pm | 773Neptune Revenue Declines 63% YoY, Shifts To CPG And Branded Products Global health and wellness company Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) revealed Monday its third-quarter financial results, on the heels of announcing the purchase of a 50.1% stake in baby food and...
-
Canopy Growth Sues GW Pharma, Alleges Unauthorized Use Of Intellectual Property
Monday, December 28, 2020 - 1:50pm | 357Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) filed an federal lawsuit last week against Britain’s GW Pharma (NASDAQ: GWPH). In the lawsuit filed in the U.S. District Court for the Western District of Texas, Canopy accuses GW Pharma of unauthorized usage of Canopy’s...
-
GW Pharma Details Positive Results Of Epidiolex Study In Patients With TSC-Related Seizures
Tuesday, December 22, 2020 - 12:52pm | 406GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology. Epidiolex is the first FDA-authorized CBD medicine for...
-
PreMarket Prep Stock Of The Day: GW Pharmaceuticals
Thursday, December 3, 2020 - 2:39pm | 702Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given...
-
GW Pharmaceuticals Revenue Hits $137M, Tests Another Cannabis Plant-Based Drug
Tuesday, November 3, 2020 - 1:00pm | 402Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...
-
DEA Deschedules Expidiolex; GW Pharma's CBD Epilepsy Treatment No Longer A Controlled Substance
Tuesday, April 7, 2020 - 11:11am | 379GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance. “This notification from DEA fully establishes that EPIDIOLEX...
-
FDA Grants GW Pharmaceuticals Priority Review For Cannabidiol Drug In Seizure Condition
Wednesday, April 1, 2020 - 12:20pm | 472A drug from GW Pharmaceuticals plc (NASDAQ: GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration. The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday...
-
GW Pharma Submits CBD Seizure Treatment To European Medicines Agency For Approval
Friday, March 13, 2020 - 10:23am | 350GW Pharmaceuticals plc (NASDAQ: GWPH) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for authorization of its Epidyolex — Epidiolex in the U.S. — cannabidiol oral solution for the management of seizures related to tuberous...
-
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
Wednesday, February 26, 2020 - 2:55pm | 485GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...